The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial

Jack A. Sargeant*, James A. King, Thomas Yates, Emma L. Redman, Danielle H. Bodicoat, Sudesna Chatterjee, Charlotte L. Edwardson, Laura J. Gray, Benoit Poulin, Ghazala Waheed, Helen L. Waller, David R. Webb, Scott A. Willis, John P.H. Wilding, Kamlesh Khunti, David J. Stensel, Melanie J. Davies

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences